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Summary We studied 100 patients with non-Hodgkin's lymphoma, 44 patients with Hodgkin's disease and
100 controls for the prevalence of the EcoRI restriction fragment polymorphism of the L-myc oncogene. No
difference in the frequency of the three genotypes (LL, LS, SS) was found between the patient and control
groups. However, the S allele was found to occur more frequently in the non-Hodgkin's lymphoma patients
(X2 = 4.57, P = 0.032). These data confirm an earlier report and suggest that the presence of the S allele is
associated with susceptibility to non-Hodgkin's lymphoma.
Associations between restriction fragment length polymor-
phisms (RFLPs) of known oncogenes and a predisposition to
develop cancer have been reported by a number of authors
(Krontiris et al., 1985; Lidereau et al., 1985; Heighway et al.,
1986). One of the most extensively studied oncogene RFLPs
is an EcoRI RFLP of the L-myc oncogene. Digestion of
DNA with EcoRI results in two alleles of 10kb (L) and
6.6 kb (S). The S allele is reported to occur more frequently
in male patients with bone and soft-tissue sarcomas (Kato et
al., 1990), in oral cancer patients with poor to moderately
differentiated tumours (Saranath et al., 1990) and in patients
with leukaemia and lymphoma (Chenevix-Trench et al.,
1989). Furthermore, an increased susceptibility to metastasis
in lung (Kawashima et al., 1988), renal (Kakehi & Yoshida,
1989) and gastric cancer (Ishizaki et al., 1990) is associated
with the presence of the S allele. However, a negative
association between an increased susceptibility to metastases
in Norwegian lung cancer patients and the S allele has been
reported (Tefre et al., 1990). In this study we have inves-
tigated the frequency of the S allele in non-Hodgkin's lym-
phoma (NHL) patients and Hodgkin's disease (HD) patients
compared with controls.
Materials and methods
Patients and controls
One hundred NHL patients (53 men and 47 women) aged
between 19 and 88 (mean age 59.1 years) and 44 HD patients
(23 men and 21 women) aged between 15 and 83 (mean age
40.7 years) agreed to provide a blood sample for this study.
The diagnosis was established in each case by standard histo-
logical techniques, confirmed in most cases by immunohisto-
logical tests. The NHL patients were classified using the
National Cancer Institute Study of classifications of non-
Hodgkin's lymphoma (1982), but statistical analysis was not
attempted because there were insufficient patients in each
subgroup. Subclassification of the HD patients was likewise
not attempted because, again, the sample size was insufficient
to analyse each group independently. One hundred unrelated,
normal, healthy donors (50 men and 50 women) aged
between 18 and 75 years (mean age 40.6 years) with no
known history of NHL or HD were used as a control
population. The ethnic composition of both the patient and
control groups was similar and all were of European de-
scent.
DNA isolation and Southern blot analysis
DNA was isolated from peripheral blood samples by the
method of Ciulla et al. (1988). Briefly, 5 ml of peripheral
blood was lysed with 45 ml of cold lysis buffer (0.32 M suc-
rose, 10 mM Tris-HCl pH 7.5, 5 mM magnesium chloride and
1% Triton X-100) and then centrifuged for 10 min at 1,000g.
The pellet was resuspended in 5 ml of 4.0 M guanidine
isothiocyanate, 25 mm sodium acetate and 0.84% P-mercap-
toethanol and rocked gently for 20 min. The DNA was
precipitated by the addition of an equal volume of iso-
propanol and resuspended in TE buffer (10 mM Tris-HCl,
1 mM EDTA, pH 8.0). A 3 ytg aliquot of DNA was digested
with EcoRI, electrophoresed in a 0.8% agarose gel, transfer-
red to Hybond N+ nylon membrane by alkaline transfer
(Chomczynski & Qasba, 1984) and hybridised with a 32p_
labelled probe prepared by the random priming method of
Feinberg and Vogelstein (1983). A 1.8 kb SmaI-EcoRI L-
myc fragment, pJB327 (Nau et al., 1985), excised from low
gelling temperature agarose, was used as the probe. Washes
were carried out at a final stringency of 0.3 x SSC and the
autoradiographs exposed for 1-3 days on Kodak XAR-5
film at -80°C.
Statistics
The frequency of the three genotypes and the two alleles in
the patient and control groups were compared using the X2
test.
Results
EcoRI-digested DNA probed with the L-myc probe results in
two fragments of 10 kb (L) and 6.6 kb (S) which are due to
an EcoRI restriction site polymorphism (Nau et al., 1985).
The distribution of the three genotypes (LL, LS, SS) in the
control and the patient groups is shown in Table I. Although
there is an increased number of patients with an SS genotype
in the NHL group, x2 analysis showed that there was no
difference in the distribution of the three genotypes between
either of the two patient groups and the controls, and all are
in accord with Hardy-Weinberg equilibrium. However, there
was a significant difference in the allele frequency between
the controls and the NHL patients. The S allele occurred
more frequently in the NHL patients than the normal control
(X2 = 4.57, 1 d.f., P= 0.032).
Discussion
Our finding of an increased frequency of the S allele in the
NHL patients confirms the results of Chenevix-Trench et al.
(1989), who reported that the S allele was more common in a
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Table I Distribution of L-myc genotypes and allele frequencies in patients and
normal controls
Genotypes Allelefrequency
LL LS SS Total X2 (P) L S x2 (P)
Controls 43 43 14 100 0.65 0.35
NHL 31 46 23 100 4.24 (0.12) 0.54 0.46 4.57 (0.032)
HD 18 18 8 44 0.44 (0.81) 0.61 0.39 0.26 (0.60)
Table II Frequency of L-myc alleles in control populations
Allelefrequency No. of
Reference L S individuals Country
Tefre et al. (1990) 0.5 0.5 129 Norway
Kato et al. (1990) 0.485 0.515 98 Japan
Kakehi and Yoshida (1989) 0.54 0.453 143 Japan
Saranath et al. (1990) 0.54 0.46 101 India
Kawashima et al. (1988) 0.415 0.575 20 Japan
Ishizaki et al. (1990) 0.49 0.51 100 Japan
Tamai et al. (1990)
White 0.57 0.43 16 USA
Black 0.15 0.85 24 USA
Farndon and Simmons (1987) 0.43 0.51 45 England
Chenevix-Trench et al. (1989)
Geriatric 0.455 0.544 112 Australia
Unselected 0.632 0.367 49
This report 0.65 0.35 100 New Zealand
combined group of acute lymphoblastic leukaemia (ALL)
and NHL patients and suggested that it may be a factor
which confers susceptibility to these haematopoietic cancers.
Although we found an increased frequency of the S allele in
the NHL patients, our data are not strictly comparable with
those of Chenevix-Trench et al. (1989) because they com-
pared a combined patient group of NHL and ALL patients,
whereas in our study separate patient groups of NHL and
HD were studied. However, if the ALL patients in Chenevix-
Trench et al.'s. study are removed the S allele still occurs
more frequently in their NHL patients (2= 6.08, 1 d.f.,
P = 0.013).
The results are, however, complicated because Chenevix-
Trench et al. (1989) used two sets of normals, geriatric (mean
age 77 years) and laboratory workers (age unknown, but
presumably younger). The increased frequency of the S allele
in the combined NHL and ALL patients was only found
when they were compared with the unselected (laboratory
workers) controls. In addition, they found a significant
difference in the genotype frequency between the geriatric
population and the unselected controls and suggested that
the LL homozygotes are less likely to reach old age. Neither
our patient nor control group falls into the geriatric category
described by Chenevix-Trench et al. (1989) so we do not
know if there is a reduced incidence of LL homozygotes in
the New Zealand elderly population.
The frequency of the L allele in our control population as
well as the unselected controls of Chenevix-Trench et al.
(1989) is considerably higher than in the other reported
studies of normals (Table II). The reason for this variation is
unclear but may reflect differences in the ethnic composition
of the various control groups. Table II shows that
Norwegians, Japanese, Indians, American Whites, English
Caucasians and geriatric Australians of European descent
have similar allele frequencies, whereas American Blacks
have an increased frequency of the S allele. In contrast, our
normal controls, as well as the unselected controls of
Chenevix-Trench et al. (1989), both of whom are of European
descent, have an increased frequency of the L allele. Differing
allele frequencies related to ethnicity are unlikely to be a
factor in the increased frequency of the S allele in the NHL
patients in our study because both our control and patient
groups were Caucasians of European descent. Nevertheless,
Table II does show the importance of ensuring that the
ethnic composition of the control and patient groups is
similar.
How the presence of a polymorphic EcoRI site is related
not only to a susceptibility to NHL but also to an increased
tendency to metastasis in other forms of cancer is not clear.
The nucleotide sequence of the S allele has been determined
(Kawashima et al., 1992) and, as expected, differs by 1 bp in
the EcoRI site. In addition, there was a deletion of 8 bp in
intron 2 and it was suggested that these differences may
influence the transcription or splicing of the S allele. An
alternative explanation is that the L-myc gene is not
involved, but is in linkage disequilibrium with a gene or
genes that are important in NHL as well as other forms of
cancer. Further studies of well-characterised large patient
groups of defined ethnicity are needed to ascertain the role of
the S allele in carcinogenesis.
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